CollPlant Biotechnologies (CLGN) Long-Term Investments (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Long-Term Investments came in at $359000.0 in Q4 2025, down 99.86% YoY from $248.0 million in Q4 2024, and up 31.5% on a QoQ basis from $273000.0 in Q2 2025.
CollPlant Biotechnologies (CLGN) Long-Term Investments (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Long-Term Investments data on file, last reported at $359000.0 in Q4 2025.
- Quarterly Long-Term Investments fell 99.86% year-over-year to $359000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $359000.0 (down 99.86% YoY) and the FY2025 annual result came in at $359000.0, down 99.86% from the prior year.
- Long-Term Investments improved to $359000.0 in Q4 2025, from $273000.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $213.0 billion in Q4 2021 to a low of $178000.0 in Q2 2021.
- A 5-year average of $11.9 billion and a median of $257000.0 in 2023 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2021 — Long-Term Investments soared 117679458.01% — and 2022, when it slumped 99.91%.
- Tracing CLGN's Long-Term Investments over 5 years: stood at $213.0 billion in 2021, then tumbled by 99.91% to $188.0 million in 2022, then sank by 99.87% to $241000.0 in 2023, then jumped by 102804.56% to $248.0 million in 2024, then slumped by 99.86% to $359000.0 in 2025.
- The last three Long-Term Investments figures came in at $359000.0 (Q4 2025), $273000.0 (Q2 2025), and $248.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 359,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Dec 31, 2024 | 248.00 Mn |
| Sep 30, 2024 | 241.00 Mn |
| Jun 30, 2024 | 236,000.00 |
| Mar 31, 2024 | 239.00 Mn |
| Dec 31, 2023 | 241,000.00 |
| Sep 30, 2023 | 226.00 Mn |
| Jun 30, 2023 | 237,000.00 |
| Mar 31, 2023 | 240,000.00 |
| Dec 31, 2022 | 188.00 Mn |
| Sep 30, 2022 | 187,000.00 |
| Jun 30, 2022 | 189,000.00 |
| Mar 31, 2022 | 208,000.00 |
| Dec 31, 2021 | 213.00 Bn |
| Sep 30, 2021 | 205,000.00 |
| Jun 30, 2021 | 178,000.00 |
| Mar 31, 2021 | 174.00 Mn |
| Dec 31, 2020 | 181,000.00 |
| Sep 30, 2020 | 169,000.00 |